Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Give him a call MOUTHMAN! He is a scientist!
Some people believe in research and science.
Some people take money from vaccine-makers.
Are you the self-proclaimed defender of vaccine-makers infallibility???
Hey MOUTHMAN, where were you when Melissa was been terminated???
Someone posted this on Facebook I thought it was interesting
Basically, RLFTF exists as 4.4 billion OS and RLFTF ADR exists as the exact same shares at a 1:150 ratio. All money filters into the original 4.4 billion. No dilution.
Perfect! ADR will be a 29.33 million float and enter the American market at $12.82 (at the current share price of 8.55 cents). Very attractive to American institutions and extremely low float.
~ Bigdog, Y@h00 RLFTF finance conversations
Government is mandating the jab, pushing it and indemnifying the vaccine maker, yes??? No??? The government, the pusher!
The hypertext link in my post will lead you to the source of the article
Believe what you want. This is the reality, some people are on take.
https://www.cnbc.com/2020/12/16/covid-vaccine-side-effects-compensation-lawsuit.html
Did a search for this —> vaccines-09-00693-v4.pdf <—
And got this
https://res.mdpi.com/d_attachment/vaccines/vaccines-09-00693/article_deploy/vaccines-09-00693-v2.pdf
But this is -v2
Dr Robert Malone, mRNA vaccine inventor, speaks out
https://rumble.com/vjlggf-dr.-robert-malone-mrna-vaccine-inventor-speaks-out-against-big-tech-censors.html
3) The new mRNA vaccines are far from safe. While the VAERS reporting system now has over 10,000 deaths (EU 20,000 deaths) after the vaccine, a whistleblower with the CDC says the actual count is closer to 50,000 and not being reported. Adverse reactions, including anaphylaxis, blood clots, neurologic injury, and spontaneous abortion have approached 650,000 patients in the USA. After only eight months of vaccination, longer-term side effects remain unknown. Instead of a push to vaccinate everyone, the vaccination program should be stopped.
4) The mRNA vaccine is not safe in pregnant women. An article in the New England Medical Journal showed a rate of spontaneous abortion of 12% which is close to what is normally expected and the conclusion was the vaccine was safe to give. However, the study was skewed to include mostly women in the third trimester (84%). The remaining women in the 1st and 2nd trimesters had a 75% spontaneous abortion rate (96 out of 127). (See the footnotes to Table 4 in the article). The CDC also tried to hide this. Pregnant women should not take the experimental vaccine.
Read more: https://www.americanthinker.com/articles/2021/08/the_bad_and_the_ugly_about_covid_in_america.html#ixzz7B7lOTCKb
Follow us: @AmericanThinker on Twitter | AmericanThinker on Facebook
HORRORS OF mRNA
Vaccine Frightening facts:
https://www.newswars.com/science-horror-vaccine-spike-protein-enters-cell-nuclei-suppresses-dna-repair-engine-will-unleash-explosion-of-cancer-immunodeficiency-autoimmune-disorders-and-accelerated-aging/
~ Shahid, Y@h00 RLFTF finance conversations
https://rumble.com/vk9omm-robert-f-kennedy-jr-sounds-the-alarm-on-truth-of-covid-vaccines-for-kids.html
…AND DO THE OTHER THINGS…
We choose to go to the Moon. We choose to go to the Moon...We choose to go to the Moon in this decade and do the other things, not because they are easy, but because they are hard; because that goal will serve to organize and measure the best of our energies and skills, because that challenge is one that we are willing to accept, one we are unwilling to postpone, and one we intend to win, and the others, too.[11]
—John F. Kennedy
Vasoactive intestinal peptide (VIP) plays important roles in many biological functions, such as, stimulation of contractility in the heart, vasodilation, promoting neuroendocrine-immune communication, lowering arterial blood pressure, and anti-inflammatory and immune-modulatory activity.
https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0280-1
Vasoactive intestinal peptide (VIP), a peptide produced by immune cells, exerts a wide spectrum of immunological functions that control the homeostasis of the immune system. In the last decade, VIP has been clearly identified as a potent anti-inflammatory factor, both in innate and adaptive immunity. In innate immunity, this peptide inhibits the production of inflammatory cytokines and chemokines from macrophages, microglia and dendritic cells.
https://pubmed.ncbi.nlm.nih.gov/16312132/
Sepsis is caused mostly by bacterial infections. The immune system runs out of controls and triggers a cytokine storm, a condition in which inflammation-causing proteins flood the blood. Organs may break down, and death often follows. Other diseases can also cause cytokine storms; medical historians believe cytokine storms were behind the lethality of the 1918-1919 flu epidemic, as well as the Black Death in the 14th century. The cytokine storm is also observed in patients with severe COVID-19 and believed to be involved in death in COVID-19.
https://today.uconn.edu/2021/01/cytokine-storms-can-kill-researchers-found-protein-sparks/
RADNOR, Pa., Aug. 30, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced an additional finding in its phase 2b/3 clinical trial investigating ZYESAMI™ (aviptadil) for the treatment of patients with acute Respiratory Failure due to Critical COVID-19. Previously announced results have focused on survival and recovery from respiratory failure at 60 days, and ZYESAMI's apparent role in preventing rise in the inflammatory cytokine IL-6, known as "Cytokine Storm."
NRx's new analysis shows that patients treated with ZYESAMI demonstrated improvement in blood oxygen, indicative of improved lung function, within a day of starting treatment. The average difference in Respiratory Distress Ratio between those treated with aviptadil and placebo was both clinically meaningful and statistically significant. Moreover, the difference is comparable to that reported a year ago from an open label study at Houston Methodist Hospital by Dr. J Georges Yousef.
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-new-finding-from-zyesami-aviptadil-phase-2b3-clinical-trial-demonstrating-clinically-significant-relief-from-respiratory-distress-in-critical-covid-19-301365091.html
WHY EXPERIMENTAL JABS WHEN THERE IS LOW TOXICITY TRUE RELIEF???
Hi All,
Been away a while thinking about things. All this talk of lawsuits, rogue CEO's, future .05 cent SP etc..
It was getting me very rattled and upset. I was losing sleep as I watched our sacred SP drop to below .08! So..
I bought 300,000 more shares at .0861 .
Keep the faith.
Never waiver in your convictions, regardless of circumstance.
Never give up.
I didn't need that car anyway... Hope the new owner enjoys it.
~ Lt. Francis, Y@h00 RLFTF finance conversations
WHY JABS…
WHY JABS…
China's COVID-19 outbreak developing rapidly, health official says
Fri, October 29, 2021, 10:01 PM
https://news.yahoo.com/mainland-china-reports-78-covid-020148673.html
NRx posted this on their LinkedIn page 2 days ago:
Irish county with 99.7% vaccination rate has highest COVID case rate
With 99.7% of adults in the Irish county of Waterford having received the COVID shots, they have the highest per-capita case rate of COVID anywhere in the country. Are they now going to suggest it's the fault of the 0.3%?!
The Irish Times reported last week that w one Waterford city district at a 14-day incidence rate of 1,486 cases per 100,000 of the population, Waterford has the highest incidence rate of anywhere in Ireland. The COVID case rate is three times the national average, which has been increasing steadily in recent weeks, despite 91% of Irish adults being vaccinated.
"Waterford has the highest rate of vaccination in the country with 99.7 per cent of adults over the age of 18 (as registered in the last census) fully vaccinated," reports the Irish Times. "The county has gone from having one of the lowest rates of Covid-19 infection in Ireland to one of the highest."
How can a vaccine that is this leaky, & apparently even counterproductive, continue to be pushed on a population even if it had zero side effects? How many more examples of this do we need to see?
And no, it's not just mild cases. Ireland has the highest number of people in the hospital with COVID since March, and the trajectory is getting worse. This is w the highest vaccination rate in the EU – over 90% of those over 16 – and it's particularly bad in the most vaccinated county of Ireland. The state's chief medical officer, Dr. Tony Holohan, said he was "increasingly worried about the rising incidence of the disease nationwide" and that the primary focus "must be to protect the most vulnerable from Covid-19." He then proceeded to blame the unvaccinated! Gee, if just 9% of those over 16 in the country are unvaccinated & just 0.3% in the worst area, what percentage of the vulnerable do you think are not vaccinated?! And wasn't the vaccine designed to protect "the most vulnerable?"
At some point, there is nowhere to run or hide from the botched vaccine that not only fails to stop transmission, but causes viral immune escape & makes more virulent variants. A recent analysis of the emergent A.30 strain published in Nature shows that "the spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies w high efficiency." This is what happens when you "shoot at the king and miss," so to speak, by fighting a virus w weak, narrow-spectrum, & waning antibodies. We've gone backward. U.K. data already shows that the vaccinated are infected at a greater rate per capita – in some cohorts twice the rate – for every age group over 30.
It's becoming clear that not only does this vaccine create greater transmission, but it also fails to protect against critical illness, especially for those who need the protection the most. Even the studies that continue to rely on old data – before the vaccines fully waned – show that the protection against critical illness doesn't really work for the immunocompromised.
A new study from Sweden published as a preprint in the Lancet claims that the vaccine efficacy against serious illness is still holding up. There's just one catch. "The effectiveness against severe illness seems to remain high through 9 months, although not for men, older frail individuals, & individuals w comorbidities," conclude the authors. Well, isn't that why we needed a vaccine in the first place? Even the Swedish study shows that after 210 days, there is zero efficacy against symptomatic infection, after which there seems to be negative efficacy. Researchers found just 52% efficacy against severe illness in all men after six months, which means you can no longer count on it for protection.
It's also important to remember that many people in Sweden – more than most other countries – already had the infection, possibly asymptomatically. So, it's possible that the efficacy of the shots is being overstated because some of those people benefited from natural immunity.
Thus, where are we nine to 12 months after the shot? Negative efficacy against symptomatic infection for all, as witnessed by the hard data in places like the U.K. & Ireland, & very low & spotty efficacy for serious illness, going down to zero for those who need it the most. But this is not cost-free. Who is to say that the effectiveness against severe illness won't go negative as well, following some sort of pattern of antibody dependent disease enhancement? Moreover, who's to say more mass vaccination of children & boosters for adults won't create even more viral immune escape that will strengthen the virus & subject people to the risks of the shots without even protecting them for another month against these new self-perpetuated mutations?
This week, the Irish parliament was issued a "stark" warning from health officials about the growing threat of the virus.
Equalizer, Y@h00 RLFTF finance conversations
Anyone see Rams post on LinkedIn?
“One day you will thank yourself for never giving up.”
~ Bigdog, Y@h00 RLFTF finance conversations
WHY JABS…
WHY JABS…
Visible events goes like that
1) Nrx was chosen to conduct trials and take care of regulatory and manufacture of Aviptadil. Starting from the idea of Relief CMO at the moment to use aviptadil for Covid. NRX has nothing more at this time nothing to do with covid, only an anti depressent. They are begging for money from GEM, no other source. Only thing to show is some big heads with supposedly good contacts in FDA.
2)Relief offers JJ a position board and 10% stake in Relief. I think this was agreed by JJ from the SEC filing from them. All good its upto them to decide
3)Now around 6 months into the trial after we see the great results, CA comes up surprisingly with 50% profit share for Nrx after the idea coming from relief and funding everything till then. Now something happend here, there is no talk about formulation at this point but CA mentions formulation and manufacturing as task of NRX
4) As soon as we hit 144 patients in November, the trial gets extended to 196. Only JJ knows why. We would have got results in December and great results if you look at the first 144
5) JJ plans to list publicly thru BRPA in Dec announcement on Dec14. At that time he did not inform public that the EUA was declined. Only after this by end of December JJ informed that it was rejected
6) In January just before Trial results Javitt starts calling it Zyesami and no mention of RLF100. This is when Javitt says RLF abandoned Aviptadil due to bad results. It is interesting that RLF at this point did not have the data. Do you can imagine who told RLF that the trial failed.
7) In February without giving the data to relief JJ makes a Conference to discuss results. This time without his dogs. The data looks not so good as he did not analyse the controls at that time. He did it without discussing with Relief when markets were open. There starts the messing up and backstabbing of RLF, GEM and the share holders of RLFTF by JJ. I think he tried at this time to get RLF share holders to NRXP.
If you look at these events, you can see an ascending greed with time. It is possible that RLF said that the trial has failed and we are late for Covid but all the information to come to this conclusion was from JJ
~ Mav, Y@h00 RLFTF finance conversations
Reply:
he gave the result of the refusal on 31.12.2020 before boarding the plane, leaving us with a price of 0.27 CHF
then he sabotaged RT at 1:50 p.m. during trading
~ Serge, Y@h00 RLFTF finance conversations
I liked @Relief's post very much - it summarizes everything about an extraordinary turn of events.
What is interesting is how, after having successfully held the pretence for quite a while, the last 3 to 4 months have just been a series of mistakes and Dr J laying out a trail of documents and SEC filings that can be used against him and NRx, a trail so damning that you even get the feeling that lawyers do not want to touch HIS stuff.
However, the main point of my post is to highlight that it is because of all the points itemized in @Relief's post that I decided two months ago to imagine in my mind that Relief is about everything else, and that everything to do with the COVID side of Aviptadil will just be a bonus if it comes through, however it eventually comes through.
Having made that decision, that is why I have now relentlessly been loading up any time the price goes below 0.087 Swiss Francs, not just to average down (0.16), but because if I exclude Dr J's stuff, that is the true current price of Relief, and that price is still a bargain considering what's coming up with Acer, APR, and Advita. The NRx share price has the possible EUA built in - in fact it can be argued that the NRx price is based entirely on the possibility of an EUA, and that's because they are on Nasdaq - for those who do not read other sources you would be amazed to see how many investors in NRx actually do not realize the product is a Relief product. So all of this is built into the NRx price, but, conversely, none of it is built in our share price when it goes below 0.087. So, even if I didn't want to average down, at that price and with zero EUA or NDA, Relief is a great bargain - that helps me remember to load up, I just treat it as a new investment.
If on top of all the other catalysts we also win EVERYTHING against NRx, whether in court or out of court, then that will be a Christmas present whatever time of the year it arrives !
~ IlkaS, Y@h00 RLFTF finance conversations
As a NRXP shareholder, lack of transparency is more than concerning. No further info about what if anything is happening in Georgia. We found out this week that Aviptadil reveived EUA if protocols are met - not Zyesami as they claimed. My guess is zero is happening, otherwise Dr. J would be pumping it. And after five months, still no answer for a drug that is supposedly a guided missle for Covid 19, being led by a highly connected man in the FDA. And yet it is like the FDA cannot be bothered by us. My next guess is that NIH results are needed to confirm the RCT results because there were so many adjustments. And the last piece that makes zero sense is the claim that Relief gave up on the drug so Nrx is entitled to it. Really? A few reasons this doesn't pass muster. Remember, the drug and trial is for Relief, not Nrx. IF Relief truly decided to shutter the project, as would be their right, then there would have been documented and legal notification. Did Nrx note this in their SEC filings that revealed so much because Dr. J said by law they had to disclose risk. Did they mention Relief giving up on the drug in January? No. Also, Relief would have informed the public. Then as late as March, Nrx still refers to Relief as their collaboration partner in PRs. Also, remember that Nrx was running the trial. They knew the results. Relief was dependent on Nrx for any info. If Relief thought Aviptadil was a failure, where would that info have come from? Think about that. Nrx also released a PR on 2/9 that tanked the RLFTF share price because of the unsuccessful data at 28 days. This theory of Nrx being able to keep Aviptadil will absolutely fall apart in court. I own bith companies, but it is becoming clear to me and many others that Dr. J is over his head as CEO and not being transparent and completely honest on matters. Hindsight is 20/20, so all I can do is wait for real answers and some approval that will provide actual revenue.
~ Relief, Y@h00 NRXP finance conversations
This is great to see. It’s objective advancements on paper that will get us to a hopeful approval, not the meaningless noise. Thanks for your effort and sharing this.
~Brian C, Y@h00 RLFTF finance conversations
COULD AVIPTADIL/SARCOIDOSIS CLINICAL TRIALS BE USED FOR BIOEQUIVALENCE STUDIES??? IS ZYESAMI A BIOEQUIVALENT OF RLF-100/AVIPTADIL???
Bioequivalence studies are special type of studies where two drugs or two sets of formulation of the same drug are compared to show that they have nearly equal bioavailability and PK/PD parameters. These studies are often done for generic drugs or when a formulation of a drug is changed during development.
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/bioequivalence
Currently, the inhalation delivery of drugs to the lungs is the most important route of administration for the treatment of severe lung diseases, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), pneumonia, pulmonary hypertension, and respiratory distress syndrome [10]. The local delivery of drugs to the lungs may allow maximum pharmacological targeting with minimum systemic exposure [11–17].
https://mdpi-res.com/d_attachment/pharmaceutics/pharmaceutics-13-01077/article_deploy/pharmaceutics-13-01077.pdf
Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial
The burden of asthma and COPD among patients is high and people affected are frequently hospitalized due to exacerbations. There are numerous reasons for the lack of disease control in asthma and COPD patients...
Authors: Claudia Gregoriano, Thomas Dieterle, Anna-Lisa Breitenstein, Selina Dürr, Amanda Baum, Sabrina Maier, Isabelle Arnet, Kurt E. Hersberger and
Jörg D. Leuppi
Citation:RESPIRATORY RESEARCH 2018 19:237
Content type: Research Published on: 3 December 2018
https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-018-0936-3
Chronic Obstructive Pulmonary Disease Market was valued at USD 10.17 Billion in 2018 and is projected to reach USD 13.9 Billion by 2026, growing at a CAGR of 4.03% from 2019 to 2026.
...
Chronic Obstructive Pulmonary Disease Market Report Scope.
https://www.verifiedmarketresearch.com/product/chronic-obstructive-pulmonary-disease-market/
The global asthma therapeutics market reached a value of US$ 17.6 Billion in 2020 and is expected to reach US$ 19.13 Billion by 2026, growing at a CAGR
https://www.imarcgroup.com/asthma-therapeutics-market
he filed ... he already has the orphan designation for sarcoidiosis, it should go quickly, they are awaiting the internal results of Leuppi
Serge, Y@h00 RLFTF finance conversations
https://www.relieftherapeutics.com/newsblog/relief-and-advita-announce-initiation-of-phase-2-trial-with-inhaled-rlf-100-for-the-prevention-of-covid-19-related-acute-respiratory-distress-syndrome
EMA is providing guidance to assist developers of potential COVID-19 treatments to prepare for eventual applications for marketing authorisation.
Aviptadil is on the list. Associated company is RLF.
So at least they are known and have received advice from EMA.
https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-covid-19/covid-19-treatments-research-development
~ IG, Y@h00 RLFTF finance conversations
DYNAMIC BUFFER, AN APR PATENTED TECHNOLOGY PLATFORM
Dynamic Buffering Technology, DBT, enabling an Immediate Release formulation of Diclofenac K (a proven non-steroidal anti-inflammatory drug – NSAID) based on a unique blend of Diclofenac and bicarbonate for a faster absorption and onset of action in comparison with conventional preparation, ensuring a more effective acute pain management and an exceptionally fast pain relief.
https://www.apr.ch/apr-pharma-products/
Diclofenac needs a prescription by your healthcare provider and is considered a more potent NSAID than ibuprofen. For arthritis, diclofenac is usually dosed as 25 to 50 mg up to a daily dose of 150 mg. Ibuprofen is prescribed at higher doses of 800 mg up to a daily dose of 3200 mg.Jan 8, 2020
https://www.singlecare.com/blog/diclofenac-vs-ibuprofen/
Diclofenac Market size is projected to reach revenue of $5.64 billion by 2025,growing at a CAGR of 3.87% during the forecast period 2020-2025.
https://www.industryarc.com/Research/Diclofenac-Market-Research-502786
In the last decade, VIP has been clearly identified as a potent anti-inflammatory factor, both in innate and adaptive immunity. In innate immunity, this peptide inhibits the production of inflammatory cytokines and chemokines from macrophages, microglia and dendritic cells.
.
.
.
The central functions that VIP plays in cellular processes is being recognized and attention is being focused on this important peptide with regard to exciting new candidates for therapeutic intervention and drug development.
https://pubmed.ncbi.nlm.nih.gov/16312132/
Amid the COVID-19 crisis, the global market for Anti-Inflammatory Therapeutics estimated at US$97.8 Billion in the year 2020, is projected to reach a revised size of US$130.9 Billion by 2026, growing at a CAGR of 4.8% over the analysis period.
https://www.prnewswire.com/news-releases/global-anti-inflammatory-therapeutics-market-to-reach-130-9-billion-by-2026--301359441.html
Does the lawsuit delay FDA approval of the EUA?
I have been in touch with the FDA on this matter and it does not.
A judge could order distribution to halt, or other actions, but that would be after FDA approval.
I suspect there are issues on manufacturing and distribution slowing the approval, unless there are concerns about the trials themselves.
It is also important for everyone to know that the FDA does not have rules prohibiting the company from speaking about why the delay is happening. The SEC may if the release of the informatiin would qualify as manipulation of the stock.
I am long and strong. As stated previously my family has over 1.5 million shares with an average cost in the mid .30's.
I remain positive about the efficacy of Aviptadil but am disappointed in the behavior of Dr. Javitt and NeuroRx, and the lack of transparency earlier on in the process about the conflicts between Dr. Javitt and Relief.
~ DanG, Y@h00 RLFTF finance conversations
Have a neighbor who had kidney problems before contracting Covid Recovered but took the vaccine and now has dialysis. Will aviptadil help his kidneys?
W, Y@h00 RLFTF finance conversations
COVID-19 — the disease caused by the coronavirus that’s led to the global pandemic —is known to damage the lungs. But, as more people become infected, more understanding of the disease emerges.
Doctors and researchers are finding that this coronavirus — officially called SARS-CoV-2—can also cause severe and lasting harm in other organs, including the heart and kidneys. C. John Sperati, M.D., M.H.S., an expert in kidney health, discusses how the new coronavirus might affect kidney function as the illness develops and afterward as a person recovers.
https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-kidney-damage-caused-by-covid19
Vasoactive intestinal peptide (VIP) has been shown to reverse pre-existing cardiac fibrosis. We sought to determine whether VIP is effective in tubulointerstitial fibrosis. Spontaneous hypertensive rats (SHR) on a 2.2% salt diet were randomised to zero time control, 4 week infusion of VIP (5 pmol/kg/min) or vehicle control infusion. A fourth group, to match the blood pressure reduction achieved in the VIP infused group was included. Fibrosis was quantitated by computerised histomorphometry, changes in pro-fibrotic mediators were measured by quantitative rt-PCR and macrophage activation assessed by cyclic adenosine monophosphate (c-AMP) response to incubation with VIP. Tubulointerstitial fibrosis in the VIP treated rats was significantly lower than the zero time control (P < 0.0005), the vehicle infused control (P < 0.0005) and the blood pressure matched group (P < 0.01). Although all six profibrotic mediators increased over the 4 week experimental period VIP infusion only decreased tumour necrosis alpha (TNFa) expression significantly (P < 0.001). Incubation of RAW264 macrophages with VIP significantly increased c-AMP (P < 0.01).
We conclude that VIP infusion reversed existing tubulointerstitial fibrosis suggesting a possible therapeutic role for a VIP based therapy in chronic kidney disease.
https://www.sciencedirect.com/science/article/pii/S0014299920300716
Some late night TV for your viewing pleasure.
This is a YouTube video that premiered Oct 12, 2021 titled
"Acer Therapeutics is going to have a BIG YEAR"
It is a 12 minute video of which the first 11 minutes is about the stock.
The altered metabolism of two essential amino acids helps drive the development of the most common and lethal form of brain cancer, new research has discovered. The findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
https://www.sciencedaily.com/releases/2016/03/160331134306.htm
Peptides have emerged as key treatments for many diseases, including cancer. Peptides have lower toxicity when compared to chemotherapeutic agents. Peptides can be used as active therapeutics or carriers to deliver anti-cancer drugs. Preclinical and clinical studies in brain tumors have shown promising results.
https://www.sciencedirect.com/science/article/abs/pii/S147148921830078X
Vasoactive intestinal peptide (VIP), a peptide produced by immune cells, exerts a wide spectrum of immunological functions that control the homeostasis of the immune system. In the last decade, VIP has been clearly identified as a potent anti-inflammatory factor, both in innate and adaptive immunity. In innate immunity, this peptide inhibits the production of inflammatory cytokines and chemokines from macrophages, microglia and dendritic cells. In addition, VIP reduces the expression of co-stimulatory molecules on antigen-presenting cells, and therefore reduces stimulation of antigen-specific CD4 T-cells. In terms of adaptive immunity, VIP promotes T-helper (Th)2-type responses, and reduces inflammatory Th1-type responses. Several of the molecular mechanisms involved in the inhibition of cytokine and chemokine expression, and in the preferential development and/or survival of Th2 effectors are known. Therefore, VIP and its analogs have been proposed as promising alternative candidates to existing therapies for the treatment of acute and chronic inflammatory and autoimmune diseases. The aim of this review is to update knowledge of the cellular and molecular events that are relevant to VIP function in the immune system. The central functions that VIP plays in cellular processes is being recognized and attention is being focused on this important peptide with regard to exciting new candidates for therapeutic intervention and drug development.
https://pubmed.ncbi.nlm.nih.gov/16312132/
Amid the COVID-19 crisis, the global market for Anti-Inflammatory Therapeutics estimated at US$97.8 Billion in the year 2020, is projected to reach a revised size of US$130.9 Billion by 2026, growing at a CAGR of 4.8% over the analysis period.
https://www.prnewswire.com/news-releases/global-anti-inflammatory-therapeutics-market-to-reach-130-9-billion-by-2026--301359441.html
WHAT ELSE COULD ZYESAMI (TM)/RLF-100/AVIPTADIL DO FOR YOU???
That NRx CEO update on the country of Georgia EUA.
I have just caught up with today's posts and seen that CEO update from Dr Javitt.
It is extraordinary. It is the most bizarre thing I have seen in a business setting. That photograph looks so unprofessional for a pharmaceutical company - it is the type of thing you would expect from someone who sold you a suspect second-hand car at the back of the market and promises to send you the paperwork later, using their phone to send you everything (maybe my imagery here does not translate well in English).
And it is called a CEO update, a "CEO update" !
If I didn't know anything about Relief, NRx Pharma, or Aviptadil, and only came to know about them today, and saw that CEO update as part of my due diligence, I would run away rather than put my money into it.
It is so bizarre that there are some specific words that come to my head, but I won't put them down.
One thing is certain : lawyers or PR are not involved in any of this output. Nothing is ever certain in law, but with this accumulation of postings that completely contradict previous postings or SEC filings, of statements being output and then deleted, of statements about Zyesami patents and then evidence that there are no patents, and of bizarreness like today's CEO update, it is looking more and more like a 70%+ likelihood of a Relief courts win, regardless of how long it takes.
And, by the way, I know about patents - our company has two. Zyesami would never be able to be patented because the Relief patents cover all angles, and patent offices check all other applicable patents before looking at a new pretender.
~ IlkaS, Y@h00 RLFTF finance conversations
Update…
https://www.nrxpharma.com/ceo-update-nation-of-georgia-emergency-use-authorization/
~ Tim, Y@h00 RLFTF finance conversations
What I wanted to post yesterday....
https://cdn.discordapp.com/attachments/884670382488051752/902199314879750144/vL_Relief_Therapeutics_Valuation_Report_25OCT21-1.pdf
~ Baxter Crewz, Y@h00 RLFTF finance conversations
So, the Application for Breakthrough Therapy Designation was submitted to the FDA on 27 September 2021. That would make the end of the 60-Day review period approximately 27 November 2021.
However, Dr. Javitt reiterated a statement made by Dr. Woodcock (FDA Acting Commissioner) at some point in the past, that the review period could take longer than 60-days due to the current work-load of FDA Staff. I do remember her having made this general statement regarding all FDA activities and reviews. I just don’t have a link to it at present.
Here’s a Link to Neuro’s “actual” Breakthrough Therapy Designation Application:
https://www.nrxpharma.com/wp-content/uploads/2021/10/Aviptadil-BTD-Sept-27-2021.pdf
Here’s a Link to Dr. Javitt’s CEO Update:
https://www.nrxpharma.com/
Anyway, I would like to say “Thank You!” to Dr. Javitt for the CEO Update on the Neuro Website, and for posting a Link to the actual Breakthrough Application. Greatly appreciated!
—Cheers—
~ Brian A, Y@h00 RLFTF finance conversations